Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKBANASDAQ:ALTNASDAQ:GERNNASDAQ:KALANASDAQ:VRNA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.37+0.7%$1.59$0.65▼$2.48$286.84M0.794.32 million shs2.09 million shsALTAltimmune$7.57+1.3%$9.39$2.09▼$14.84$536.64M0.055.43 million shs3.12 million shsGERNGeron$3.50-6.2%$2.77$1.64▼$4.05$1.91B0.6111.19 million shs10.38 million shsKALAKALA BIO$6.50+2.7%$7.41$5.10▼$19.35$18.33M-1.8526,031 shs5,284 shsVRNAVerona Pharma$15.59-0.8%$16.45$11.83▼$23.81$1.26B0.41498,755 shs359,325 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-2.16%-37.33%-2.86%+106.03%ALTAltimmune+8.10%-1.06%-17.73%-25.45%+29.02%GERNGeron+1.08%+8.12%+12.69%+75.12%+39.70%KALAKALA BIO-3.95%-9.57%-20.78%-11.96%-59.81%VRNAVerona Pharma0.00%-0.51%-2.18%-7.75%-32.59%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.6545 of 5 stars3.52.00.04.02.40.80.6ALTAltimmune1.5813 of 5 stars3.32.00.00.03.21.70.0GERNGeron2.9029 of 5 stars3.53.00.01.30.01.70.6KALAKALA BIO3.7094 of 5 stars3.55.00.04.40.60.80.0VRNAVerona Pharma1.1513 of 5 stars3.50.00.00.02.01.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics3.00Buy$5.00264.96% UpsideALTAltimmune2.67Moderate Buy$15.0098.15% UpsideGERNGeron3.00Buy$5.3352.38% UpsideKALAKALA BIO3.00Buy$18.00176.92% UpsideVRNAVerona Pharma3.00Buy$33.60115.52% UpsideCurrent Analyst RatingsLatest ALT, VRNA, AKBA, GERN, and KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024VRNAVerona PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$31.00 ➝ $36.004/11/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.004/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.003/28/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.003/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/15/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$194.62M1.47N/AN/A($0.16) per share-8.56ALTAltimmune$430K1,247.99N/AN/A$2.75 per share2.75GERNGeron$240K7,975.19N/AN/A$0.46 per share7.61KALAKALA BIO$3.89M4.71N/AN/A$2.79 per share2.33VRNAVerona Pharma$460K2,739.10N/AN/A$3.10 per share5.03Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.28N/AN/AN/A-26.32%N/A-20.36%5/13/2024 (Estimated)ALTAltimmune-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)GERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)KALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)VRNAVerona Pharma-$54.37M-$0.69N/AN/AN/AN/A-20.47%-17.72%5/14/2024 (Estimated)Latest ALT, VRNA, AKBA, GERN, and KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023KALAKALA BION/A-$3.18-$3.18-$3.18N/AN/A3/27/2024Q4 2023ALTAltimmune-$0.35-$0.33+$0.02-$0.12N/A$0.04 million3/14/2024Q4 2023AKBAAkebia Therapeutics-$0.04-$0.04N/AN/A$55.64 million$56.20 million2/29/2024Q4 2023VRNAVerona Pharma-$0.23-$0.16+$0.07-$0.16N/AN/A2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.181.03ALTAltimmuneN/A17.2617.26GERNGeron0.143.163.16KALAKALA BIO5.106.336.33VRNAVerona Pharma0.2033.3333.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ALTAltimmune78.05%GERNGeron73.71%KALAKALA BIO24.61%VRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.84%ALTAltimmune4.10%GERNGeron3.00%KALAKALA BIO13.40%VRNAVerona Pharma4.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics167209.37 million201.33 millionOptionableALTAltimmune5970.89 million67.99 millionOptionableGERNGeron141546.87 million530.47 millionOptionableKALAKALA BIO432.82 million2.44 millionNot OptionableVRNAVerona Pharma7980.82 million76.94 millionOptionableALT, VRNA, AKBA, GERN, and KALA HeadlinesSourceHeadlineVerona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandleramericanbankingnews.com - April 17 at 3:36 AMVerona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgradeamericanbankingnews.com - April 17 at 1:08 AMVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrademarketbeat.com - April 16 at 10:36 AMVerona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandlermarketbeat.com - April 16 at 8:33 AMVerona Pharma (NASDAQ:VRNA) Shares Up 4.9%marketbeat.com - April 4 at 3:08 PMAmerican Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA)marketbeat.com - March 28 at 4:07 AMVRNA Apr 2024 17.500 callfinance.yahoo.com - March 16 at 8:32 AMVRNA Apr 2024 15.000 callfinance.yahoo.com - March 16 at 3:31 AMAndrew Fisher Joins Verona Pharma as General Counselglobenewswire.com - March 4 at 2:00 AMBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipelinemarkets.businessinsider.com - March 1 at 1:10 PMVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:10 PM3 Healthcare Stocks That Have Outperformed Nvidia Since 2022fool.com - March 1 at 8:45 AMVerona Pharma plc 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 29 at 11:18 AMVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 10:48 AMVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 10:48 AMVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - February 29 at 2:00 AMVerona Pharma earnings preview: what to expectmarkets.businessinsider.com - February 28 at 1:35 PMWhen Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?finance.yahoo.com - February 25 at 12:52 PMVerona Pharma PLC ADRwsj.com - February 25 at 7:52 AMVRNA Mar 2024 15.000 putfinance.yahoo.com - February 17 at 7:46 PMVRNA Jun 2024 30.000 callfinance.yahoo.com - February 17 at 2:46 PMVerona Pharma: A Few Points From The Bull And Bear Caseseekingalpha.com - February 15 at 5:55 PMVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Updatefinance.yahoo.com - February 15 at 10:20 AMVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Updateglobenewswire.com - February 15 at 2:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks With Unusual Call Option ActivityMarch 26, 2024 1:10 PMView 3 Stocks With Unusual Call Option ActivityTop 3 Stocks Bought By Members of Congress In the First QuarterMarch 25, 2024 8:55 AMView Top 3 Stocks Bought By Members of Congress In the First QuarterAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentApril 3, 2024 9:10 AMView Akebia Therapeutics Surges on FDA Approval for Anemia Treatment3M Spun Off Its Health Division, Is It Still A Buy?April 4, 2024 7:47 AMView 3M Spun Off Its Health Division, Is It Still A Buy?4 Dividend Aristocrats Trading at a DiscountApril 1, 2024 6:10 AMView 4 Dividend Aristocrats Trading at a DiscountAll Headlines Company DescriptionsAkebia TherapeuticsNASDAQ:AKBAAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.AltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.GeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Verona PharmaNASDAQ:VRNAVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.